MyFinsight
Home
Blog
About
Total revenue
$150,321K
Gross profit
$108,549K
Other income, net
$3,543K
Canceled cashflow
$41,772K
Net income
$25,490K
(320.14%↑ Y/Y)
Stock-based compensation
$14,086K
(-35.81%↓ Y/Y)
Accrued liabilities and
deferred revenue
$6,637K
(417.41%↑ Y/Y)
Proceeds from the
exercise of common stock...
$8,433K
(76.39%↑ Y/Y)
Canceled cashflow
$86,602K
Depreciation and
amortization
$4,838K
(-55.41%↓ Y/Y)
Accounts payable
$1,171K
(-62.38%↓ Y/Y)
Operating lease
liabilities
$772K
(165.09%↑ Y/Y)
Noncash lease expense
$704K
(-56.00%↓ Y/Y)
Effect of foreign
currency on operations
-$11K
(-100.22%↓ Y/Y)
Deferred income taxes
$1K
(-98.65%↓ Y/Y)
Loss on disposal of
property, plant and...
-$1K
(93.33%↑ Y/Y)
Cost of
revenue-Testing
$36,309K
Intangible asset
amortization - cost of revenue
$2,741K
Cost of
revenue-Product
$2,515K
Cost of
revenue-Biopharmaceutical And Other
$207K
Net cash provided by
operating activities
$45,826K
(17.60%↑ Y/Y)
Net cash used in
financing activities
$4,139K
(158.71%↑ Y/Y)
Canceled cashflow
$7,885K
Canceled cashflow
$4,294K
Total research and
development
$29,442K
Total selling and
marketing
$28,263K
Total general and
administrative
$27,443K
Income tax provision
$1,033K
Intangible asset
amortization - operating...
$421K
Laboratory supplies and
reagents expense
$13,847K
Compensation expense
$9,858K
Other cost
$5,883K
Sample collection
expense
$3,644K
Allocation of facilities
and it expenses
$3,077K
Product costs
$1,985K
License fees and
royalties
$336K
Other cost
$190K
Allocation of facilities
and it expenses
$4K
Other cost
$207K
Decrease in cash, cash
equivalents and restricted...
$36,420K
(280.97%↑ Y/Y)
Canceled cashflow
$13,545K
Accounts receivable
$4,162K
(-2.83%↓ Y/Y)
Supplies
$1,240K
Prepaid expenses and
other current assets
$1,123K
(-79.43%↓ Y/Y)
Amortization of discount on
short-term investments
$723K
Other assets
$319K
(-77.03%↓ Y/Y)
Revaluation of
acquisition-related contingent...
-$318K
(88.95%↑ Y/Y)
Proceeds from maturity of
short-term investments
$50,935K
(-0.25%↓ Y/Y)
Payment of taxes on
vested restricted...
$4,294K
(-63.71%↓ Y/Y)
Net decrease in
cash, cash...
$36,394K
(286.85%↑ Y/Y)
Canceled cashflow
$26K
Net cash used in
investing activities
-$13,545K
(73.97%↑ Y/Y)
Canceled cashflow
$50,935K
Effect of foreign
currency on cash, cash...
-$26K
(-104.02%↓ Y/Y)
Purchase of short-term
investments
$59,999K
(-40.00%↓ Y/Y)
Purchases of property,
plant and equipment
$2,859K
(-7.92%↓ Y/Y)
Issuance of loan
receivable
$1,622K
Back
Back
Cash Flow
VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT)
source: myfinsight.com